J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

JINTSBIO-NewLaunch

More Like This

PR Newswire associated0

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy

PR Newswire associated0

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

UK-backed AI companies to transform British cancer care and spark new drug breakthroughs

Oncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative Medicine

PR Newswire associated0

J INTS BIO, Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, accepted for presentation at the upcoming American Association for Cancer Research 2024 meeting in USA (AACR 2024)

PR Newswire associated0

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

PR Newswire associated0

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

PR Newswire associated0

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance